Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Single women risk rape and exploitation in search for better life in Europe - 2At least 171 measles cases confirmed in 9 states, CDC data shows
- 3Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- 4What to know about King Charles III's cancer treatment and his message to the public
- 5No injuries after blast at pro-Israel centre in the Netherlands
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Vote in favor of Your #1 4\u00d74 SUVs
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Russian strikes on Ukraine kill 5 people and wound 30 more
- Esteem Stuffed Gaming Workstations to Consider
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- Ukrainian troops showed 'greater tactical imagination' than Western trainers, British officer says, pointing to their ambush tactics
